San Luis Wealth Advisors LLC Acquires 24,883 Shares of Bristol-Myers Squibb (NYSE:BMY)

San Luis Wealth Advisors LLC grew its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 26.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 117,958 shares of the biopharmaceutical company’s stock after purchasing an additional 24,883 shares during the period. Bristol-Myers Squibb comprises approximately 1.3% of San Luis Wealth Advisors LLC’s holdings, making the stock its 19th largest holding. San Luis Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $6,103,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. ESL Trust Services LLC bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at about $27,000. LGT Financial Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 227 shares during the period. MFA Wealth Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $39,000. Fairman Group LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $42,000. Finally, Beach Investment Counsel Inc. PA bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $42,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $52.41 on Friday. The company’s 50 day moving average price is $49.69 and its two-hundred day moving average price is $46.43. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $57.65. The firm has a market cap of $106.26 billion, a PE ratio of -16.08, a PEG ratio of 13.75 and a beta of 0.46. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The company had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same quarter in the prior year, the firm posted $1.75 EPS. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. Equities research analysts predict that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.58%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -73.62%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BMY shares. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. BMO Capital Markets reiterated a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, September 23rd. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. TD Cowen upped their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday. Finally, Jefferies Financial Group upped their price target on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research note on Wednesday, August 28th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $53.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.